JP2017528496A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528496A5
JP2017528496A5 JP2017515948A JP2017515948A JP2017528496A5 JP 2017528496 A5 JP2017528496 A5 JP 2017528496A5 JP 2017515948 A JP2017515948 A JP 2017515948A JP 2017515948 A JP2017515948 A JP 2017515948A JP 2017528496 A5 JP2017528496 A5 JP 2017528496A5
Authority
JP
Japan
Prior art keywords
compound
hydrogen
fluorine
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017515948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528496A (ja
JP6517925B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/071656 external-priority patent/WO2016046164A1/de
Publication of JP2017528496A publication Critical patent/JP2017528496A/ja
Publication of JP2017528496A5 publication Critical patent/JP2017528496A5/ja
Application granted granted Critical
Publication of JP6517925B2 publication Critical patent/JP6517925B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017515948A 2014-09-24 2015-09-22 置換されたオキソピリジン誘導体 Expired - Fee Related JP6517925B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14186082 2014-09-24
EP14186082.5 2014-09-24
PCT/EP2015/071656 WO2016046164A1 (de) 2014-09-24 2015-09-22 Substituierte oxopyridin-derivate

Publications (3)

Publication Number Publication Date
JP2017528496A JP2017528496A (ja) 2017-09-28
JP2017528496A5 true JP2017528496A5 (cg-RX-API-DMAC7.html) 2018-10-11
JP6517925B2 JP6517925B2 (ja) 2019-05-22

Family

ID=51589181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515948A Expired - Fee Related JP6517925B2 (ja) 2014-09-24 2015-09-22 置換されたオキソピリジン誘導体

Country Status (7)

Country Link
US (1) US20170298052A1 (cg-RX-API-DMAC7.html)
EP (1) EP3197873B1 (cg-RX-API-DMAC7.html)
JP (1) JP6517925B2 (cg-RX-API-DMAC7.html)
CN (1) CN106687458B (cg-RX-API-DMAC7.html)
CA (1) CA2961981A1 (cg-RX-API-DMAC7.html)
ES (1) ES2713624T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016046164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2722423T3 (es) * 2014-09-24 2019-08-12 Bayer Pharma AG Derivados de oxopiridina sustituidos
US20190119213A1 (en) * 2015-03-19 2019-04-25 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
UA126251C2 (uk) * 2018-02-27 2022-09-07 Джянгсу Хенгруй Медісін Ко., Лтд. Кристалічна форма похідної оксопіколінаміду та спосіб її отримання
ES2922533T3 (es) 2018-04-10 2022-09-16 Bayer Pharma AG Un derivado de oxopiridina sustituido
EP3898634A1 (en) 2018-12-21 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
AR117435A1 (es) 2018-12-21 2021-08-04 Bayer Ag Derivados de oxopiridina sustituidos
CN112022848B (zh) * 2020-08-13 2022-02-22 中南大学湘雅二医院 索拉非尼在治疗1型糖尿病中的应用
CN115947680B (zh) * 2021-10-09 2025-09-23 山东新时代药业有限公司 一种替罗非班中间体化合物及其制备方法
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
NZ572418A (en) * 2006-05-05 2011-08-26 Millennium Pharm Inc Factor xa inhibitors
WO2008079787A2 (en) * 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
KR102011534B1 (ko) * 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 XIa 억제제로서 피리디논 및 피리미디논 유도체

Similar Documents

Publication Publication Date Title
JP2017528496A5 (cg-RX-API-DMAC7.html)
JP2016535031A5 (cg-RX-API-DMAC7.html)
JP2016515562A5 (cg-RX-API-DMAC7.html)
JP2016525136A5 (cg-RX-API-DMAC7.html)
JP2016535732A5 (cg-RX-API-DMAC7.html)
JP2018519323A5 (cg-RX-API-DMAC7.html)
JP2013542261A5 (cg-RX-API-DMAC7.html)
MX2015013437A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares.
CN105636951A (zh) 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用
RU2009136445A (ru) Способ получения высокочистого празугрель гидрохлорида
JP2014114295A5 (cg-RX-API-DMAC7.html)
JP2014509316A5 (cg-RX-API-DMAC7.html)
JP2012041365A5 (cg-RX-API-DMAC7.html)
JP2018516883A5 (cg-RX-API-DMAC7.html)
JP2016539092A5 (cg-RX-API-DMAC7.html)
JP2012532112A5 (cg-RX-API-DMAC7.html)
JP2018509426A5 (cg-RX-API-DMAC7.html)
JP2014521625A5 (cg-RX-API-DMAC7.html)
JP2009510044A5 (cg-RX-API-DMAC7.html)
JP2014508811A5 (cg-RX-API-DMAC7.html)
CA2864222A1 (en) Cycloalkane derivative
JP2015514061A5 (cg-RX-API-DMAC7.html)
JP2016503785A5 (cg-RX-API-DMAC7.html)
JP2019531279A5 (cg-RX-API-DMAC7.html)
RU2015155585A (ru) 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента